Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN XL versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN XL versus ERYC 125.
BIAXIN XL vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
500 mg orally once daily for 7 to 14 days
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic